Bayer Corporation

Molecular Diagnostics, Inc.

Bayer Corporation (formerly Molecular Diagnostics, Inc.)

Thomas R Barnett

James J Elting

Michael E Kamarck

Axel W Kretschmer

Nanibhushan Dattagupta

Donald M Crothers

William Jeffrey Allard

Peter M Rae

Support jack

A nucleic acid comprising a base sequence which codes for a CEA family member peptide sequence or nucleic acids having a base sequence hybridizable therewith, replicable recombinant cloning vehicles having an insert comprising such nucleic acid, cells transfected, infected or injected with such cloning vehicles, polypeptides expressed by such cells, synthetic peptides derived from the coding sequence of CEA family member nucleic acids, antibody preparations specific for such polypeptides, immunoassays for detecting CEA family members using such antibody preparations and nucleic acid hybridization methods for detecting CEA family member nucleic acid sequences using a nucleic acid probe comprising the above described nucleic acid.

cDNAs coding for members of the carcinoembryonic antigen family

Antibody preparations specifically binding to unique determinants of CEA

A nucleic acid comprising a base sequence which codes for a CEA peptide sequence or nucleic acids having a base sequence hybridizable therewith, replicable recombinant cloning vehicles having an insert comprising such nucleic acid, cells transfected, infected or infected with such cloning vehicles, polypeptides expressed by such cells, antibody preparations specific for such polypeptides, immunoassays for detecting CEA using such antibody preparations and nucleic acid hybridization methods for detecting a CEA nucleic acid sequence using a nucleic acid probe comprising the above described nucleic acid.

CDNA coding for carcinoembryonic antigen

A method for aiding in the diagnosis of, and monitoring the progression of, breast cancer in a patient by measuring the amount of NCA 50/90 in a blood sample, e.g. serum sample, obtained from the patient. Measurement in a single sample of an amount of NCA 50/90 significantly higher than the mean amount of NCA 50/90 in the normal population is an indication of breast cancer in the patient. The progression of breast cancer can also be monitored by performing a series of specific immunoassays over time to determine changes in the level of NCA 50/90 in blood samples. Increases in blood NCA 50/90 levels over time are indicative of a deteriorating condition whereas decreasing levels of blood NCA 50/90 over time indicate an improving condition.

Monitoring of NC 50/90 in blood samples of breast cancer patients

A nucleic acid encoding a carcinoembryonic antigen (CEA) that cross-reacts with human CEA is described. In addition, vectors and host cells containing such nucleic acids are disclosed.

Nucleic acid sequences are disclosed that encode carcinoembryonic antigens (CEAs) as are replicable recombinant cloning vehicles containing DNA that encodes CEA proteins.

cDNA coding for carcinoembryonic antigen (CEA)

CDNAS coding for members of the carcinoembryonic antigen family

This invention relates to a nucleic acid comprising a base sequence which codes for a CEA family member peptide sequence or nucleic acids having a base sequence hybridizable therewith, replicable recombinant cloning vehicles having an insert comprising such nucleic acid, cells transfected, infected or injected with such cloning vehicles, polypeptides expressed by such cells, synthetic peptides derived from the coding sequence of CEA family member nucleic acids, antibody preparations specific for such polypeptides, immunoassays for detecting CEA family members using such antibody preparations and nucleic acid hybridization methods for detecting CEA family member nucleic acid sequences using a nucleic acid probe comprising the above described nucleic acid.

A process for production of a single strand of a nucleic acid comprising covalently linking to a solid substrate a polynucleotide complementary to the desired strand, hybridizing said polynucleotide with an oligonucleotide, extending the oligonucleotide in direction away from said substrate, denaturing the hybridized polynucleotide and extended oligonucleotide, thereby to free the extended oligonucleotide from the solid substrate, and separating the extended oligonucleotide. The product can be used for making analytical probes.

Growing community of inventors

East Haven, CT, United States of America

Thomas R Barnett